Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIL Therapy in Pediatric Malignant Solid Tumors
NCT06047977Phase 1Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Jun 2025
- Primary completion
- Sep 2029
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of autologous tumor-infiltrating lymphocytes in malignant solid tumor, sponsored by Moffitt Cancer Center. Started Jun 2025; status: recruiting.
02
Drugs
autologous tumor-infiltrating lymphocytes
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT06047977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06047977.